THERACRYF PLC

Report Publication Announcement • Nov 24, 2025

National Storage Mechanism | Additional information

RNS Number : 6294I

Theracryf PLC

24 November 2025

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Notice of Half Year results

Alderley Park, 24 November 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on neuropsychiatry and oncology, announces that the Company's half year results for the six months to 30 September 2025 will be released on Wednesday, 3 December 2025.

A live presentation of the results will be given at 11am GMT on 3 December, via Investor Meet Company by Dr Huw Jones, CEO, Toni Hänninen, CFO and Dr Helen Kuhlman, COO.

The results presentation will be open to all existing and potential shareholders. Questions can be submitted up to 24 hours prior to either event via the Investor Meet Company dashboard or during the live presentations.

Investors who already follow TheraCryf plc on the Investor Meet Company platform will automatically be invited. New registrants can sign up to Investor Meet Company HERE.

-Ends-

Enquiries

TheraCryf plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, COO	+44 (0)1625 315 090 [email protected]
Singer Capital Markets (NOMAD & Joint Broker) Phil Davies / Oliver Platts / Patrick Weaver	+44 (0)20 7496 3000
Turner Pope Investments (Joint Broker) James Pope / Andy Thacker	+44 (0)20 3657 0050
Vigo Consulting Rozi Morris/ Melanie Toyne Sewell	+44 (0)20 7390 0230 [email protected]

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma* and neurodevelopmental disorders [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders.  The Company has sourced know-how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORBJBFTMTITBMA